Nasus Pharma (NSRX) 6-K: Nov 2025 corporate presentation, Exhibit 99.1

Nasus Pharma Ltd. filed a Form 6-K noting that on November 3, 2025, it made an updated corporate presentation available on its website.

Accepted by SEC EDGAR 11/03/2025 - 08:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nasus Pharma Ltd. filed a Form 6-K noting that on November 3, 2025, it made an updated corporate presentation available on its website. The presentation is furnished as Exhibit 99.1.

The company states the presentation is not a prospectus or offering document and does not constitute an invitation or offer to sell or solicit the purchase of any securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nasus Pharma (NSRX) announce in this 6-K?

The company made an updated corporate presentation available on its website and furnished it as Exhibit 99.1.

When was the Nasus Pharma corporate presentation made available?

It was made available on November 3, 2025.

Where can investors find the updated Nasus Pharma presentation?

It is available on the company’s website and attached to the 6-K as Exhibit 99.1.

Does the Nasus Pharma presentation constitute an offer to sell securities?

No. The filing states it is not a prospectus or offering document and is not an offer or solicitation.

What form did Nasus Pharma use for this disclosure?

A Form 6-K Report of Foreign Private Issuer.

What is included in the exhibit to the 6-K?

Exhibit 99.1 contains the corporate presentation dated November 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On November 3, 2025, Nasus Pharma Ltd. (the “Company”) made available an updated corporate presentation on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

The information contained in the corporate presentation does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of the Company.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Corporate Presentation, dated November 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: November 3, 2025	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer